CompletedPhase 4NCT05657860

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Studying Prader-Willi syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Maimonides Medical Center
Principal Investigator
Deepan Singh, MD
Maimonides Medical Center
Intervention
Guanfacine Extended Release(drug)
Enrollment
15 enrolled
Eligibility
6-35 years · All sexes
Timeline
2020 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05657860 on ClinicalTrials.gov

Other trials for Prader-Willi syndrome

Additional recruiting or active studies for the same condition.

See all trials for Prader-Willi syndrome →

← Back to all trials